DK2215223T3 - Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser - Google Patents
Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenserInfo
- Publication number
- DK2215223T3 DK2215223T3 DK08845549.8T DK08845549T DK2215223T3 DK 2215223 T3 DK2215223 T3 DK 2215223T3 DK 08845549 T DK08845549 T DK 08845549T DK 2215223 T3 DK2215223 T3 DK 2215223T3
- Authority
- DK
- Denmark
- Prior art keywords
- mechanucleases
- single chain
- recognition sequences
- constructed single
- rationally constructed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US124707P | 2007-10-31 | 2007-10-31 | |
| PCT/US2008/082072 WO2009059195A2 (en) | 2007-10-31 | 2008-10-31 | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2215223T3 true DK2215223T3 (da) | 2013-07-22 |
Family
ID=40591777
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08845549.8T DK2215223T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser |
| DK13165733.0T DK2660317T3 (en) | 2007-10-31 | 2008-10-31 | Rationally designed single-chain meganucleases with non-palindromic recognition sequences |
| DK16163925.7T DK3098309T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13165733.0T DK2660317T3 (en) | 2007-10-31 | 2008-10-31 | Rationally designed single-chain meganucleases with non-palindromic recognition sequences |
| DK16163925.7T DK3098309T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser |
Country Status (8)
| Country | Link |
|---|---|
| US (10) | US8445251B2 (enExample) |
| EP (4) | EP3578646A3 (enExample) |
| JP (7) | JP5761996B2 (enExample) |
| AU (1) | AU2008318430A1 (enExample) |
| CA (1) | CA2704383A1 (enExample) |
| DK (3) | DK2215223T3 (enExample) |
| ES (3) | ES2422291T3 (enExample) |
| WO (1) | WO2009059195A2 (enExample) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| WO2003078619A1 (en) † | 2002-03-15 | 2003-09-25 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| EP3578646A3 (en) | 2007-10-31 | 2020-03-18 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| CA2781693C (en) | 2009-11-27 | 2018-12-18 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| AU2010325564A1 (en) | 2009-11-27 | 2012-07-12 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| DE112010004582T5 (de) | 2009-11-27 | 2012-11-29 | Basf Plant Science Company Gmbh | Optimierte Endonukleasen und Anwendungen davon |
| US20130198897A1 (en) | 2010-03-22 | 2013-08-01 | Philip Morris Products S.A. | Modifying enzyme activity in plants |
| WO2012138901A1 (en) * | 2011-04-05 | 2012-10-11 | Cellectis Sa | Method for enhancing rare-cutting endonuclease efficiency and uses thereof |
| DK2714936T3 (en) | 2011-06-01 | 2019-03-25 | Prec Biosciences Inc | METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES |
| EP2612918A1 (en) | 2012-01-06 | 2013-07-10 | BASF Plant Science Company GmbH | In planta recombination |
| WO2013166113A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
| EP3116533B1 (en) | 2014-03-12 | 2020-08-12 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| CN106714826A (zh) | 2014-09-07 | 2017-05-24 | 西莱克塔生物科技公司 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
| ES2905181T3 (es) | 2015-05-01 | 2022-04-07 | Prec Biosciences Inc | Deleción precisa de secuencias cromosómicas in vivo |
| CA2985816A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| EP4115894A1 (en) | 2015-06-19 | 2023-01-11 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
| WO2017024407A1 (en) | 2015-08-11 | 2017-02-16 | The Royal Institution For The Advancement Of Learning/Mcgill University | Peptidic tgf-beta antagonists |
| EP4530354A3 (en) | 2015-09-08 | 2025-09-10 | Precision Biosciences, Inc. | Treatment of retinitis pigmentosa using engineered meganucleases |
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| AU2016333898B2 (en) | 2015-10-05 | 2020-11-12 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
| WO2017112859A1 (en) | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| US11274288B2 (en) | 2016-02-16 | 2022-03-15 | Emendobio Inc. | Compositions and methods for promoting homology directed repair mediated gene editing |
| DK3429603T3 (da) | 2016-03-15 | 2022-03-14 | Childrens Medical Center | Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller |
| CA3017645C (en) | 2016-04-27 | 2021-07-13 | University Of Puerto Rico | 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases |
| JP2019514397A (ja) | 2016-05-03 | 2019-06-06 | プレシジョン バイオサイエンシズ，インク． | 血友病ａの治療に有用な操作されたヌクレアーゼ |
| MX2018015798A (es) | 2016-06-22 | 2019-07-12 | Univ North Carolina State | Método para incrementar la eficiencia de uso de nitrógeno y/o la eficiencia de utilización de nitrógeno en plantas. |
| EP3487994A4 (en) * | 2016-07-25 | 2020-01-29 | Bluebird Bio, Inc. | HOMING BCL11A ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
| WO2018039333A1 (en) | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| DK3510157T5 (da) | 2016-09-08 | 2024-09-02 | 2Seventy Bio Inc | Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse |
| AU2017338846B2 (en) | 2016-10-04 | 2020-09-24 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
| US10662416B2 (en) * | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| AU2017346683B2 (en) * | 2016-10-17 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | TGFβR2 endonuclease variants, compositions, and methods of use |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| JP7352807B2 (ja) | 2017-04-12 | 2023-09-29 | マジェンタ セラピューティクス インコーポレイテッド | アリール炭化水素受容体アンタゴニスト及びその使用 |
| KR20230170125A (ko) * | 2017-04-21 | 2023-12-18 | 프리시젼 바이오사이언시스 인코포레이티드 | Pcsk9 유전자 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018201144A1 (en) | 2017-04-28 | 2018-11-01 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| AU2018266698A1 (en) | 2017-05-08 | 2019-11-28 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| KR102590466B1 (ko) | 2017-05-25 | 2023-10-19 | 2세븐티 바이오, 인코포레이티드 | Cblb 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
| CA3067842C (en) | 2017-06-23 | 2025-11-04 | Univ Kentucky Res Found | Methods of modulating the alkaloid content of a plant or part thereof |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| JP2020529206A (ja) | 2017-07-31 | 2020-10-08 | アール・ジエイ・レイノルズ・タバコ・カンパニー | 植物におけるウイルスベースの遺伝子編集のための方法及び組成物 |
| US20200239544A1 (en) | 2017-10-03 | 2020-07-30 | Precision Biosciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| WO2019070974A1 (en) * | 2017-10-04 | 2019-04-11 | Bluebird Bio, Inc. | PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
| AU2018347583A1 (en) | 2017-10-13 | 2020-05-21 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector IgM responses |
| EP3703715A1 (en) | 2017-10-31 | 2020-09-09 | Magenta Therapeutics, Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
| US20190314407A1 (en) | 2017-10-31 | 2019-10-17 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
| WO2019089913A1 (en) | 2017-11-01 | 2019-05-09 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
| JP2021505172A (ja) | 2017-12-06 | 2021-02-18 | マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 造血幹細胞及び前駆細胞を動員させるための投薬レジメン |
| US20210002621A1 (en) * | 2017-12-20 | 2021-01-07 | Bluebird Bio, Inc. | Ctla4 homing endonuclease variants, compositions, and methods of use |
| JP2021510150A (ja) | 2018-01-03 | 2021-04-15 | マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 造血幹細胞および前駆細胞の増幅ならびに遺伝性代謝障害の処置のための組成物および方法 |
| CN111819285B (zh) | 2018-01-09 | 2024-08-09 | 希博斯美国有限公司 | 防碎基因和突变 |
| CA3092372A1 (en) | 2018-02-26 | 2019-08-29 | AnTolRx, Inc. | Tolerogenic liposomes and methods of use thereof |
| EA202092382A1 (ru) | 2018-04-04 | 2021-02-02 | САЙБАС ЮЭс ЛЛС | Гены fad2 и мутации |
| IT201800004253A1 (it) | 2018-04-05 | 2019-10-05 | Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria. | |
| KR102617818B1 (ko) | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US20210230565A1 (en) * | 2018-04-27 | 2021-07-29 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bruton's tyrosine kinase homing endonuclease variants, compositions, and methods of use |
| BR112020025439A2 (pt) | 2018-06-14 | 2021-03-16 | Bluebird Bio, Inc. | Receptores de antígenos quiméricos cd79a |
| GB201812603D0 (en) | 2018-08-02 | 2018-09-19 | British American Tobacco Investments Ltd | Method |
| KR20210071976A (ko) | 2018-09-04 | 2021-06-16 | 마젠타 테라퓨틱스 인코포레이티드 | 아릴 하이드로카본 수용체 길항제 및 사용 방법 |
| WO2020072059A1 (en) * | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| GB201817971D0 (en) | 2018-11-02 | 2018-12-19 | British American Tobacco Investments Ltd | Method |
| GB201818715D0 (en) | 2018-11-16 | 2019-01-02 | British American Tobacco Investments Ltd | Method |
| CA3122278A1 (en) | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Homing endonuclease variants |
| US20220090047A1 (en) | 2018-12-21 | 2022-03-24 | Precision Biosciences, Inc. | Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria |
| GB201900940D0 (en) | 2019-01-23 | 2019-03-13 | British American Tobacco Investments Ltd | Method |
| AU2020253538A1 (en) | 2019-04-03 | 2021-11-18 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
| US20220204994A1 (en) | 2019-04-05 | 2022-06-30 | Precision Biosciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| CA3137975A1 (en) | 2019-05-07 | 2020-11-12 | Precision Biosciences, Inc. | Optimization of engineered meganucleases for recognition sequences |
| GB201906768D0 (en) | 2019-05-14 | 2019-06-26 | British American Tobacco Investments Ltd | Method |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| GB201909562D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
| GB201909563D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
| JP2022544825A (ja) | 2019-08-20 | 2022-10-21 | プレシジョン バイオサイエンシズ，インク． | 細胞免疫療法のためのリンパ球枯渇投与レジメン |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| US20220401481A1 (en) | 2019-11-01 | 2022-12-22 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| FI4069729T3 (fi) | 2019-12-06 | 2025-04-01 | Prec Biosciences Inc | Optimoidut muokatut meganukleaasit, joilla on spesifisyys tunnistussekvenssiä varten hepatiitti b -virusgenomissa |
| EP3835309A1 (en) | 2019-12-13 | 2021-06-16 | KWS SAAT SE & Co. KGaA | Method for increasing cold or frost tolerance in a plant |
| WO2021158915A1 (en) | 2020-02-06 | 2021-08-12 | Precision Biosciences, Inc. | Recombinant adeno-associated virus compositions and methods for producing and using the same |
| WO2021205000A2 (en) | 2020-04-09 | 2021-10-14 | R.J. Reynolds Tobacco Company | Method |
| US20230330185A1 (en) | 2020-04-27 | 2023-10-19 | Magenta Therapeutics, Inc. | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| JP2023526310A (ja) | 2020-05-12 | 2023-06-21 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 導入遺伝子発現のｄｒｇ特異的低減のための組成物 |
| US20230193230A1 (en) | 2020-05-12 | 2023-06-22 | Precision Biosciences, Inc. | Treatment of retinitis pigmentosa using improved engineered meganucleases |
| EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| CA3172292A1 (en) | 2020-08-21 | 2022-02-24 | Cassandra GORSUCH | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
| US20230365995A1 (en) | 2020-10-07 | 2023-11-16 | Precision Biosciences, Inc. | Lipid nanoparticle compositions |
| WO2022094180A1 (en) | 2020-10-29 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Aav capsids and compositions containing same |
| EP4244342A1 (en) | 2020-11-12 | 2023-09-20 | Precision BioSciences, Inc. | Engineered meganucleases having specificity for recognition sequences in the dystrophin gene |
| CA3172161A1 (en) | 2021-01-08 | 2022-07-14 | James Jefferson Smith | Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene |
| EP4284823A1 (en) | 2021-01-28 | 2023-12-06 | Precision BioSciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
| AU2022262778A1 (en) | 2021-04-22 | 2023-11-30 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
| EP4326861B1 (en) | 2021-04-22 | 2025-12-17 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
| WO2022226316A1 (en) | 2021-04-22 | 2022-10-27 | Precision Biosciences, Inc. | Compositions and methods for generating male sterile plants |
| AR125467A1 (es) | 2021-04-27 | 2023-07-19 | Univ Pennsylvania | Cápsides de virus adenoasociados derivados de porcinos y usos de los estos |
| WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| WO2023070003A1 (en) | 2021-10-19 | 2023-04-27 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| AU2022368911A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| MX2024009603A (es) | 2022-02-03 | 2024-08-14 | Nicoventures Trading Ltd | Metodo. |
| WO2023148476A1 (en) | 2022-02-03 | 2023-08-10 | Nicoventures Trading Limited | Method of modulating alkaloid content in tobacco plants |
| KR20240132133A (ko) | 2022-02-04 | 2024-09-02 | 니코벤처스 트레이딩 리미티드 | 담배 식물들에서 알칼로이드 함량을 조절하는 방법 |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| GB202205148D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
| GB202205149D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
| GB202205561D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
| GB202205562D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
| GB202206107D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
| GB202206109D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2024015966A2 (en) | 2022-07-15 | 2024-01-18 | The Trustees Of The University Of Pennsylvania | Recombinant aav having aav clade d and clade e capsids and compositions containing same |
| WO2024056902A2 (en) | 2022-09-16 | 2024-03-21 | Christopher Shaw | Compositions and methods for treating neurological diseases |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| AU2023392154A1 (en) | 2022-12-14 | 2025-06-26 | King's College London | Compositions and methods for treating neurological diseases |
| AU2024206812A1 (en) | 2023-01-05 | 2025-08-14 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
| GB202300905D0 (en) | 2023-01-20 | 2023-03-08 | Nicoventures Trading Ltd | Method |
| WO2024161022A2 (en) | 2023-02-03 | 2024-08-08 | King's College London | Compositions and methods for treating neurological diseases |
| KR20250141243A (ko) | 2023-02-06 | 2025-09-26 | 블루록 테라퓨틱스 엘피 | 데그론 융합 단백질 및 그의 생산 및 사용 방법 |
| TW202448928A (zh) | 2023-03-02 | 2024-12-16 | 美商艾羅伊治療公司 | 抗cd22抗體及其用途 |
| GB202303077D0 (en) | 2023-03-02 | 2023-04-19 | Univ Oslo | Brassica plants with improved seed retention |
| AU2024255934A1 (en) | 2023-04-14 | 2025-11-20 | Precision Biosciences, Inc. | Muscle-specific expression cassettes |
| WO2024216116A1 (en) | 2023-04-14 | 2024-10-17 | Precision Biosciences, Inc. | Muscle-specific expression cassettes |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
| WO2025083169A1 (en) | 2023-10-17 | 2025-04-24 | Tenpoint Therapeutics Limited | Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders |
| WO2025101946A1 (en) | 2023-11-08 | 2025-05-15 | Precision Biosciences, Inc. | Polypeptide linkers for use in engineered meganucleases |
| WO2025126153A2 (en) | 2023-12-14 | 2025-06-19 | Aviadobio Ltd. | Compositions and methods for treating sod1-mediated neurological diseases |
| WO2025233894A1 (en) | 2024-05-09 | 2025-11-13 | University Of Miami | Engineered meganucleases that target human mitochondrial genomes |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US6156304A (en) | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US6593308B2 (en) | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
| AU2002317771A1 (en) * | 2001-06-05 | 2002-12-16 | Cellectis | Methods for modifying the cpg content of polynucleotides |
| AU2003210996A1 (en) * | 2002-02-11 | 2003-09-04 | Zymogenetics, Inc. | Materials and methods for preparing dimeric growth factors |
| WO2003078619A1 (en) * | 2002-03-15 | 2003-09-25 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| JP2006518372A (ja) | 2003-01-28 | 2006-08-10 | セレクティス | 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用 |
| JP4095622B2 (ja) * | 2004-03-31 | 2008-06-04 | キヤノン株式会社 | 金結合性複合タンパク質 |
| EP1591521A1 (en) * | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
| DK1863909T3 (da) * | 2005-03-15 | 2010-08-30 | Cellectis | I-CreI-meganukleasevarianter med modificeret specificitet, fremgangsmåde til fremstilling og anvendelser deraf |
| WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| WO2007034262A1 (en) | 2005-09-19 | 2007-03-29 | Cellectis | Heterodimeric meganucleases and use thereof |
| EP1764414A1 (en) * | 2005-09-17 | 2007-03-21 | Icon Genetics AG | Plant viral particles comprising a plurality of fusion proteins consisting of a plant viral coat protein, a peptide linker and a recombinant protein and use of such plant viral particles for protein purification |
| US8021867B2 (en) * | 2005-10-18 | 2011-09-20 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
| WO2007049095A1 (en) | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| EP1957520A4 (en) * | 2005-11-29 | 2009-05-27 | Univ Virginia Commonwealth | POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN |
| WO2007093836A1 (en) | 2006-02-13 | 2007-08-23 | Cellectis | Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof |
| GB0603099D0 (en) * | 2006-02-16 | 2006-03-29 | Lontra Environmental Technolog | Rotary piston and cylinder devices |
| WO2008010009A1 (en) | 2006-07-18 | 2008-01-24 | Cellectis | Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof |
| SG176487A1 (en) | 2006-11-14 | 2011-12-29 | Cellectis | Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof |
| WO2008059317A1 (en) | 2006-11-14 | 2008-05-22 | Cellectis | Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof |
| WO2008093152A1 (en) | 2007-02-01 | 2008-08-07 | Cellectis | Obligate heterodimer meganucleases and uses thereof |
| AU2007347328B2 (en) | 2007-02-19 | 2013-03-07 | Cellectis | LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof |
| WO2008102199A1 (en) * | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| WO2008149176A1 (en) * | 2007-06-06 | 2008-12-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof |
| EP2167666A2 (en) | 2007-06-29 | 2010-03-31 | Pioneer Hi-Bred International Inc. | Methods for altering the genome of a monocot plant cell |
| EP3578646A3 (en) | 2007-10-31 | 2020-03-18 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| WO2009074842A1 (en) | 2007-12-13 | 2009-06-18 | Cellectis | Improved chimeric meganuclease enzymes and uses thereof |
-
2008
- 2008-10-31 EP EP19167904.2A patent/EP3578646A3/en active Pending
- 2008-10-31 WO PCT/US2008/082072 patent/WO2009059195A2/en not_active Ceased
- 2008-10-31 CA CA2704383A patent/CA2704383A1/en not_active Abandoned
- 2008-10-31 EP EP16163925.7A patent/EP3098309B1/en active Active
- 2008-10-31 ES ES08845549T patent/ES2422291T3/es active Active
- 2008-10-31 EP EP08845549.8A patent/EP2215223B1/en active Active
- 2008-10-31 AU AU2008318430A patent/AU2008318430A1/en not_active Abandoned
- 2008-10-31 JP JP2010532293A patent/JP5761996B2/ja active Active
- 2008-10-31 EP EP13165733.0A patent/EP2660317B1/en active Active
- 2008-10-31 DK DK08845549.8T patent/DK2215223T3/da active
- 2008-10-31 DK DK13165733.0T patent/DK2660317T3/en active
- 2008-10-31 ES ES13165733.0T patent/ES2575412T3/es active Active
- 2008-10-31 DK DK16163925.7T patent/DK3098309T3/da active
- 2008-10-31 ES ES16163925T patent/ES2732735T3/es active Active
-
2010
- 2010-04-30 US US12/771,163 patent/US8445251B2/en active Active
-
2013
- 2013-05-20 US US13/897,923 patent/US20130267009A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/723,840 patent/US20150337335A1/en not_active Abandoned
- 2015-06-08 JP JP2015115646A patent/JP6050861B2/ja active Active
- 2015-09-18 US US14/858,989 patent/US9434931B2/en active Active
- 2015-09-18 US US14/858,986 patent/US9340777B2/en active Active
-
2016
- 2016-04-19 US US15/132,941 patent/US10041053B2/en active Active
- 2016-09-30 JP JP2016193485A patent/JP2017051190A/ja active Pending
-
2018
- 2018-07-02 US US16/025,747 patent/US20180340160A1/en not_active Abandoned
- 2018-11-22 JP JP2018219205A patent/JP2019062898A/ja active Pending
-
2020
- 2020-10-23 US US17/079,377 patent/US20210054354A1/en not_active Abandoned
- 2020-11-27 JP JP2020196770A patent/JP2021052770A/ja active Pending
-
2022
- 2022-11-25 JP JP2022187981A patent/JP2023029894A/ja active Pending
-
2023
- 2023-03-17 US US18/185,726 patent/US12351839B2/en active Active
-
2024
- 2024-10-24 JP JP2024187133A patent/JP2025028832A/ja active Pending
-
2025
- 2025-01-17 US US19/029,758 patent/US20250154485A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2215223T3 (da) | Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser | |
| DE602007005217D1 (de) | Fahrradkette | |
| EP2132315A4 (en) | REOVIRUS HAVING MODIFIED SEQUENCES | |
| BRPI0914889A2 (pt) | peptídeo glp-1 adicionado de cadeia oligossacarídica | |
| EP2209394A4 (en) | Armtasche | |
| BRPI0811497A2 (pt) | Arquitetura multiprocessador com encadeamento otimizado | |
| DE502008000295D1 (de) | Nockenwelle | |
| BRPI0718796A2 (pt) | Nucleotídeo | |
| DK2087307T3 (da) | Med afstand anbragt letvægtskompositpanser | |
| EP2262892A4 (en) | EXPRESSION OF HETEROLOGOUS SEQUENCES | |
| DE602007004088D1 (de) | Kettenförderer | |
| EP2433766A4 (en) | CHAINSAW | |
| EP2222427A4 (en) | GRID INSERT | |
| EP2162436A4 (en) | NEW CASE OF RENININHIBITORS | |
| FR2910111B3 (fr) | Tronconneuse | |
| EP2318537A4 (en) | OPTIMIZED PROMOTER SEQUENCE | |
| DE112008002937A5 (de) | Geräuscharmer Kettentrieb | |
| AT508202A3 (de) | Metallriemenkalander | |
| AT504336B8 (de) | Kettenrad | |
| DE112009000779A5 (de) | Galvanisierungsverfahren | |
| ES1066538Y (es) | Llavero | |
| ES1068660Y (es) | Llavero | |
| UA15228S (uk) | Медальйон з ланцюжком | |
| FI20065600A0 (fi) | Kampiakseli | |
| GB0805010D0 (en) | Chain and sprocket guard |